Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 51, pages 1644–1646 (2016)Cite this article

Subjects

Over the past decade, many studies in poor-risk Hodgkin lymphoma (HL) have reported experiences with allo-HSCT.1 The relapse rate after allo-hematopoietic stem cell transplantation (HSCT) remains high, ranging from 31 to 81%, and patients relapsing after allo-HSCT have a dismal survival rate, as reported in two retrospective studies.2, 3

The aim of the current retrospective study was to report the outcomes of a series of HL patients who relapsed/progressed after allo-HSCT, which was performed at two associated centers (Istituto Clinico Humanitas, Rozzano, Italy, n=28; Institut Paoli Calmettes, Marseille, France, n=13).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Castagna L, Carlo-Stella C, Mazza R, Santoro A . Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2014; 7: 2015015.

    Article  Google Scholar 

  2. Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1537–1545.

    Article  Google Scholar 

  3. Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ . Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant 2011; 17: 1497–1504.

    Article  Google Scholar 

  4. Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 2010; 115: 2763–2768.

    Article  CAS  Google Scholar 

  5. Ulaner GA, Lilienstein J, Gönen M, Maragulia J, Moskowitz CH, Zelenetz AD . False-positive [18 F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. J Clin Oncol 2014; 32: 51–56.

    Article  Google Scholar 

  6. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–2189.

    Article  CAS  Google Scholar 

  7. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.

    Article  Google Scholar 

  8. Crocchiolo R, Castagna L, Garciaz S, Fürst S, El Cheikh J, Sarina B et al. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica 2015; 100: e423–e427.

    Article  Google Scholar 

  9. Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013; 31: 59–63.

    Article  Google Scholar 

  10. Sala E, Crocchiolo R, Gandolfi S, Bruno-Ventre M, Bramanti S, Peccatori J et al. Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1444–1447.

    Article  CAS  Google Scholar 

  11. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560–568.

    Article  CAS  Google Scholar 

  12. Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist 2015; 20: 323–328.

    Article  CAS  Google Scholar 

  13. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–666.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all personnel working at the Hematology Department and Cellular Therapy Unit both in Paoli-Calmettes Institute and Humanitas Cancer Center for their remarkable contribution to patient care and the assistance provided to the patients’ families.

Author contributions

LC and BS designed the study, collected and analyzed the data, and wrote the article. RC performed the statistical analysis. All authors critically revised the article for important intellectual content and approved it for publication.

Author information

Authors and Affiliations

  1. Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy

    L Castagna, B Sarina, R Crocchiolo, S Bramanti, S Furst, R Devillier, L Morabito, S Harbi, A Rimondo, P Jean Weiller, C Carlo-Stella, A Santoro & D Blaise

  2. Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy

    D Coso, R Bouabdallah & D Blaise

  3. Intensive Care Unit, Institut Paoli Calmettes, Marseille, France

    D Mokart

  4. Biostatistical Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy

    L Giordano

  5. Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy

    C Carlo-Stella

  6. Humanitas University, Rozzano, Italy

    A Santoro

  7. Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France

    C Chabannon

  8. Aix-Marseille Université, Marseille, France

    C Chabannon & D Blaise

  9. Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France

    C Chabannon & D Blaise

Authors
  1. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Sarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Devillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Mokart
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Harbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Rimondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Jean Weiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C Carlo-Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Castagna.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castagna, L., Sarina, B., Crocchiolo, R. et al. Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. Bone Marrow Transplant 51, 1644–1646 (2016). https://doi.org/10.1038/bmt.2016.257

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.257

This article is cited by

Search

Advanced search

Quick links